1 Caswell-Jin JL, Zimmer AD, Stedden W, Kingham KE, Zhou AY and Kurian AW: Cascade genetic testing of relatives for hereditary cancer risk: Results of an online initiative. J Natl Cancer Inst 111(1): 95-98, 2019. PMID: 30239769. DOI:10.1093/jnci/djy147
2 Dawood S, Austin L and Cristofanilli M: Cancer stem cells: implications for cancer therapy. Oncology (Williston Park) 28(12): 1101-7, 1110, 2014. PMID: 25510809.
3 Batlle E and Clevers H: Cancer stem cells revisited. Nat Med 23(10): 1124-1134, 2017. PMID: 28985214. DOI: 10.1038/nm.4409
4 Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ and Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 100(7): 3983-3988, 2003. PMID: 12629218. DOI: 10.1073/pnas.0530291100
5 Kida K, Ishikawa T, Yamada A, Shimada K, Narui K, Sugae S, Shimizu D, Tanabe M, Sasaki T, Ichikawa Y and Endo I: Effect of ALDH1 on prognosis and chemoresistance by breast cancer subtype. Breast Cancer Res Treat 156(2): 261-269, 2016. PMID:26975188. DOI: 10.1007/s10549-016-3738-7
6 Yamada A, Suzuki C, Shima H, Kida K, Adachi S, Yamamoto S, Narui K, Tanabe M, Shimizu D, Taniguchi R, Oshi M, Takabe K, Miyagi Y, Ichikawa Y, Ishikawa T and Endo I: Aldehyde dehydrogenase 1-related genes in triple-negative breast cancer investigated using network analysis. Anticancer Res 40(12): 6733- 6742, 2020. PMID: 33288566. DOI: 10.21873/anticanres.14696
7 Wu SY and Chiang CM: The double bromodomain-containing chromatin adaptor Brd4 and transcriptional regulation. J Biol Chem 282(18): 13141-13145, 2007. PMID: 17329240. DOI: 10.1074/jbc.R700001200
8 Donati B, Lorenzini E and Ciarrocchi A: BRD4 and Cancer: going beyond transcriptional regulation. Mol Cancer 17(1): 164, 2018. PMID: 30466442. DOI: 10.1186/s12943-018-0915-9
9 Filippakopoulos P, Picaud S, Mangos M, Keates T, Lambert JP, Barsyte-Lovejoy D, Felletar I, Volkmer R, Müller S, Pawson T, Gingras AC, Arrowsmith CH and Knapp S: Histone recognition and large-scale structural analysis of the human bromodomain family. Cell 149(1): 214-231, 2012. PMID: 22464331. DOI: 10.1016/j.cell.2012.02.013
10 Taniguchi Y: The Bromodomain and Extra-Terminal Domain (BET) family: Functional anatomy of BET paralogous proteins. Int J Mol Sci 17(11): 1849, 2016. PMID: 27827996. DOI: 10.3390/ijms17111849
11 Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, Kastritis E, Gilpatrick T, Paranal RM, Qi J, Chesi M, Schinzel AC, McKeown MR, Heffernan TP, Vakoc CR, Bergsagel PL, Ghobrial IM, Richardson PG, Young RA, Hahn WC, Anderson KC, Kung AL, Bradner JE and Mitsiades CS: BET bromodomain inhibition as a therapeutic strategy to target c- Myc. Cell 146(6): 904-917, 2011. PMID: 21889194. DOI: 10.1016/j.cell.2011.08.017
12 Sancisi V, Manzotti G, Gugnoni M, Rossi T, Gandolfi G, Gobbi G, Torricelli F, Catellani F, Faria do Valle I, Remondini D, Castellani G, Ragazzi M, Piana S and Ciarrocchi A: RUNX2 expression in thyroid and breast cancer requires the cooperation of three non-redundant enhancers under the control of BRD4 and c-JUN. Nucleic Acids Res 45(19): 11249-11267, 2017. PMID:28981843. DOI: 10.1093/nar/gkx802
13 Ferri E, Petosa C and McKenna CE: Bromodomains: Structure, function and pharmacology of inhibition. Biochem Pharmacol 106: 1-18, 2016. PMID: 26707800. DOI: 10.1016/j.bcp.2015.12.005
14 Shimamura T, Chen Z, Soucheray M, Carretero J, Kikuchi E, Tchaicha JH, Gao Y, Cheng KA, Cohoon TJ, Qi J, Akbay E, Kimmelman AC, Kung AL, Bradner JE and Wong KK: Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer. Clin Cancer Res 19(22): 6183-6192, 2013. PMID:24045185. DOI: 10.1158/1078-0432.CCR-12-3904
15 Shu S, Lin CY, He HH, Witwicki RM, Tabassum DP, Roberts JM, Janiszewska M, Huh SJ, Liang Y, Ryan J, Doherty E, Mohammed H, Guo H, Stover DG, Ekram MB, Brown J, D’Santos C, Krop IE, Dillon D, McKeown M, Ott C, Qi J, Ni M, Rao PK, Duarte M, Wu SY, Chiang CM, Anders L, Young RA, Winer E, Letai A, Barry WT, Carroll JS, Long H, Brown M, Liu XS, Meyer CA, Bradner JE and Polyak K: Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer. Nature 529(7586): 413-417, 2016. PMID:26735014. DOI: 10.1038/nature16508
16 Shi J, Wang Y, Zeng L, Wu Y, Deng J, Zhang Q, Lin Y, Li J, Kang T, Tao M, Rusinova E, Zhang G, Wang C, Zhu H, Yao J, Zeng YX, Evers BM, Zhou MM and Zhou BP: Disrupting the interaction of BRD4 with diacetylated Twist suppresses tumorigenesis in basal-like breast cancer. Cancer Cell 25(2): 210- 225, 2014. PMID: 24525235. DOI: 10.1016/j.ccr.2014.01.028
17 Yamada A, Ishikawa T, Ota I, Kimura M, Shimizu D, Tanabe M, Chishima T, Sasaki T, Ichikawa Y, Morita S, Yoshiura K, Takabe K and Endo I: High expression of ATP-binding cassette transporter ABCC11 in breast tumors is associated with aggressive subtypes and low disease-free survival. Breast Cancer Res Treat 137(3): 773-782, 2013. PMID: 23288347. DOI: 10.1007/s10549-012-2398-5
18 Allred DC, Harvey JM, Berardo M and Clark GM: Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11(2): 155-168, 1998. PMID: 9504686.
19 Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF, American Society of Clinical Oncology and College of American Pathologists: Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31(31): 3997-4013, 2013. PMID: 24101045. DOI: 10.1200/JCO.2013.50.9984
20 Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, Cerami E, Sander C and Schultz N: Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6(269): pl1, 2013. PMID: 23550210. DOI: 10.1126/scisignal.2004088
21 Liu J, Lichtenberg T, Hoadley KA, Poisson LM, Lazar AJ, Cherniack AD, Kovatich AJ, Benz CC, Levine DA, Lee AV, Omberg L, Wolf DM, Shriver CD, Thorsson V, Cancer Genome Atlas Research Network and Hu H: An integrated TCGA pan- cancer clinical data resource to drive high-quality survival outcome analytics. Cell 173(2): 400-416.e11, 2018. PMID: 29625055. DOI: 10.1016/j.cell.2018.02.052
22 Lovén J, Hoke HA, Lin CY, Lau A, Orlando DA, Vakoc CR, Bradner JE, Lee TI and Young RA: Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 153(2): 320- 334, 2013. PMID: 23582323. DOI: 10.1016/j.cell.2013.03.036
23 Du Z, Song X, Yan F, Wang J, Zhao Y and Liu S: Genome-wide transcriptional analysis of BRD4-regulated genes and pathways in human glioma U251 cells. Int J Oncol 52(5): 1415-1426, 2018. PMID: 29568956. DOI: 10.3892/ijo.2018.4324
24 Akıncılar SC, Khattar E, Boon PL, Unal B, Fullwood MJ and Tergaonkar V: Long-Range chromatin interactions drive mutant TERT promoter activation. Cancer Discov 6(11): 1276-1291, 2016. PMID: 27650951. DOI: 10.1158/2159-8290.CD-16-0177
25 Lu L, Chen Z, Lin X, Tian L, Su Q, An P, Li W, Wu Y, Du J, Shan H, Chiang CM and Wang H: Inhibition of BRD4 suppresses the malignancy of breast cancer cells via regulation of Snail. Cell Death Differ 27(1): 255-268, 2020. PMID:31114028. DOI: 10.1038/s41418-019-0353-2
26 Lee M, Tayyari F, Pinnaduwage D, Bayani J, Bartlett JMS, Mulligan AM, Bull SB and Andrulis IL: Tumoral BRD4 expression in lymph node-negative breast cancer: association with T-bet+ tumor-infiltrating lymphocytes and disease-free survival. BMC Cancer 18(1): 750, 2018. PMID: 30029633. DOI: 10.1186/s12885-018-4653-6
27 Zhong L, Yang Z, Lei D, Li L, Song S, Cao D and Liu Y: Bromodomain 4 is a potent prognostic marker associated with immune cell infiltration in breast cancer. Basic Clin Pharmacol Toxicol 128(1): 169-182, 2021. PMID: 32799413. DOI: 10.1111/bcpt.13481
28 Crawford NP, Alsarraj J, Lukes L, Walker RC, Officewala JS, Yang HH, Lee MP, Ozato K and Hunter KW: Bromodomain 4 activation predicts breast cancer survival. Proc Natl Acad Sci USA 105(17): 6380-6385, 2008. PMID: 18427120. DOI: 10.1073/pnas.0710331105
29 Fernandez P, Scaffidi P, Markert E, Lee JH, Rane S and Misteli T: Transformation resistance in a premature aging disorder identifies a tumor-protective function of BRD4. Cell Rep 9(1): 248-260, 2014. PMID: 25284786. DOI: 10.1016/j.celrep.2014.08.069
30 Wu SY, Lee CF, Lai HT, Yu CT, Lee JE, Zuo H, Tsai SY, Tsai MJ, Ge K, Wan Y and Chiang CM: Opposing functions of BRD4 isoforms in breast cancer. Mol Cell 78(6): 1114-1132.e10, 2020. PMID: 32446320. DOI: 10.1016/j.molcel.2020.04.034
31 Zhang S and Roeder RG: The long and the short of BRD4: Two tales in breast cancer. Mol Cell 78(6): 993-995, 2020. PMID: 32559427. DOI: 10.1016/j.molcel.2020.05.033
32 Bai L, Zhou B, Yang CY, Ji J, McEachern D, Przybranowski S, Jiang H, Hu J, Xu F, Zhao Y, Liu L, Fernandez-Salas E, Xu J, Dou Y, Wen B, Sun D, Meagher J, Stuckey J, Hayes DF, Li S, Ellis MJ and Wang S: Targeted degradation of BET proteins in triple-negative breast cancer. Cancer Res 77(9): 2476-2487, 2017. PMID: 28209615. DOI: 10.1158/0008-5472.CAN-16-2622
33 Doroshow DB, Eder JP and LoRusso PM: BET inhibitors: a novel epigenetic approach. Ann Oncol 28(8): 1776-1787, 2017. PMID: 28838216. DOI: 10.1093/annonc/mdx157
34 Lewin J, Soria JC, Stathis A, Delord JP, Peters S, Awada A, Aftimos PG, Bekradda M, Rezai K, Zeng Z, Hussain A, Perez S, Siu LL and Massard C: Phase Ib trial with birabresib, a small-molecule inhibitor of bromodomain and extraterminal proteins, in patients with selected advanced solid tumors. J Clin Oncol 36(30): 3007-3014, 2018. PMID: 29733771. DOI: 10.1200/JCO.2018.78.2292
35 Filippakopoulos P: What is the BET on solid tumors? J Clin Oncol 36(30): 3040-3042, 2018. PMID: 29847297. DOI: 10.1200/JCO.2018.78.8695